Rituximab in refractory sarcoidosis: A single centre experience

被引：43

作者：

Cinetto F. ^{[1
]}

Compagno N. ^{[1
]}

Scarpa R. ^{[1
]}

Malipiero G. ^{[1
]}

Agostini C. ^{[1
]}

机构：

[1] Padova University Hospital, Clinical Immunology, Department of Medicine-DIMED, via Giustiniani 2, Padua

来源：

Clinical and Molecular Allergy | / 13卷 / 1期

关键词：

Granulomatosis; Refractory sarcoidosis; Rituximab;

D O I：

10.1186/s12948-015-0025-9

中图分类号：

学科分类号：

摘要：

Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature. © 2015 Cinetto et al.

引用

共 17 条

[1] Hunninghake G.W., Costabel U., Ando M., Baughman R., Cordier J.F., du Bois R., Et al., ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders, Sarcoidosis Vasc Diffuse Lung Dis, 16, pp. 149-173, (1999)
[2] Crommelin H.A., Vorselaars A.D., Moorsel C.H., Korenromp I.H., Deneer V.H., Grutters J.C., Anti-TNF therapeutics for the treatment of sarcoidosis, Immunotherapy, 6, pp. 1127-1143, (2014)
[3] Facco M., Cabrelle A., Teramo A., Olivieri V., Gnoato M., Teolato S., Et al., Sarcoidosis is a Th1/Th17 multisystem disorder, Thorax, 66, pp. 144-150, (2011)
[4] Lee N.S., Barber L., Akula S.M., Sigounas G., Kataria Y.P., Arce S., Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis, Clin Vaccine Immunol, 18, pp. 1306-1316, (2011)
[5] Geetha D., Hruskova Z., Segelmark M., Hogan J., Morgan M.D., Cavero T., Et al., Rituximab for treatment of severe renal disease in ANCA associated vasculitis, J Nephrol, (2015)
[6] Munoz S.A., Gandino I.J., Orden A.O., Allievi A., Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis, Reumatol Clin, 11, pp. 165-169, (2015)
[7] Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Et al., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, 83, pp. 435-445, (1994)
[8] Puechal X., Gottenberg J.E., Berthelot J.M., Gossec L., Meyer O., Morel J., Et al., Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry, Arthritis Care Res Hoboken, 64, pp. 331-339, (2012)
[9] Alberici F., Jayne D.R., Impact of rituximab trials on the treatment of ANCA-associated vasculitis, Nephrol Dial Transplant, 29, pp. 1151-1159, (2014)
[10] Alberici F., Smith R.M., Jones R.B., Roberts D.M., Willcocks L.C., Chaudhry A., Et al., Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis, Rheumatology, 54, 7, pp. 1153-1160, (2015)

← 1 2 →